PINE BROOK, N.J., July 30 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing proprietary Heteropoloymer (HP) Antibodies for the treatment of life-threatening infectious diseases, today announced the appointment of Ron Eastman as Chairman of the Board of Directors, succeeding William R. Miller. Mr. Eastman is a Partner at Essex Woodlands Health Ventures. Mr. Miller, a former Vice Chairman of Bristol-Myers Squibb, will remain on the Board as a Director.
